Top Markets
#1 TENDIES TENDIES +46.86%
#2 Cash Cat Cash Cat +33.26%
#3 Threshold Network Threshold Network +19.02%
#4 Asteroid Shiba Asteroid Shiba +17.67%
#5 OSK OSK +15.80%
#6 龙虾 (Lobster) 龙虾 (Lobster) +13.42%
#7 Ape and Pepe Ape and Pepe +12.62%
#8 Magma Finance Magma Finance +11.22%
#9 MarsCoin MarsCoin +10.44%
#10 Kite Kite +9.98%
Coin of the day
TENDIES TENDIES
Settings
Language
ENGLISH
Currency
USD
Theme
VISEN Pharmaceuticals VISEN Pharmaceuticals

VISEN Pharmaceuticals

2561
Rank in Stocks #16898
VISEN Pharmaceuticals operates as an investment holding company, concentrating... VISEN Pharmaceuticals operates as an investment holding company, concentrating on the development and commercialization of endocrine treatments across mainland China, Hong Kong, and Taiwan. Their flagship product, Lonapegsomatropin, offers a once-weekly, long-acting growth hormone replacement designed for pediatric growth hormone deficiency. The company is also progressing other therapies, such as TransCon CNP (navepegritide), a long-acting prodrug utilizing c-type natriuretic peptide for achondroplasia, and Palopegteriparatide, a daily parathyroid hormone replacement therapy intended for chronic hypoparathyroidism. VISEN has forged strategic collaborations with Shanghai Pharmaceutical and United Family Healthcare. The enterprise was founded in 2018 and is based in Suzhou, China.
Share Price
$2.46
Market Cap
$268.65M
Change (1 day)
-1.73%
Change (1 year)
-57.06%
Country
CN
Trade VISEN Pharmaceuticals (2561)

Category

Healthcare
P/E ratio for VISEN Pharmaceuticals (2561)
P/E ratio as of 2026 TTM: 0
According to VISEN Pharmaceuticals latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for VISEN Pharmaceuticals from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 38.38 -
IN
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.